KD Logo

Selling Buzz: Nurix Therapeutics Inc [NRIX] Chief Legal Officer Ring Christine sells 3,290 shares of the company

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nurix Therapeutics Inc shares valued at $82,250 were sold by Ring Christine on Nov 04 ’24. At $25.00 per share, Ring Christine sold 3,290 shares. The insider’s holdings dropped to 28,084 shares worth approximately $0.76 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, CHRISTINE RING purchased 3,290 shares, netting a total of over 80,506 in proceeds.

Before that, Ring Christine had sold 5,760 shares from its account. In a trade valued at $139,867, the Chief Legal Officer traded Nurix Therapeutics Inc shares for $24.28 each. Upon closing the transaction, the insider’s holdings decreased to 5,760 shares, worth approximately $0.76 million.

As published in their initiating research note from UBS on October 24, 2024, Nurix Therapeutics Inc [NRIX] has been a Buy and the price target has been revised to $35. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid October. Earlier on July 31, 2024, Truist initiated its rating. Their recommendation was “a Buy” for NRIX stock.

Analyzing NRIX Stock Performance

During the last five days, there has been a surge of approximately 12.17%. Over the course of the year, Nurix Therapeutics Inc shares have jumped approximately 161.63%. Shares of the company reached a 52-week high of $27.60 on 10/28/24 and a 52-week low of $7.65 on 01/29/24. A 50-day SMA is recorded $24.26, while a 200-day SMA reached $18.02. Nevertheless, trading volume fell to 4.46 million shares from 0.76 million shares the previous day.

Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)

According to the 24-hour chart, there is a support level at 26.35, which, if violated, would cause prices to drop to 25.71. In the upper region, resistance lies at 27.46. The next price resistance is at 27.92. RSI (Relative Strength Index) is 63.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.50, which suggests the price will decrease in the coming days. Percent R is at 14.67%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular